Lantern Pharma Inc. (LTRN)
$3.60
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Key data on LTRN
Market cap
$40263923
EPS
-1.75
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.602799
Price on LTRN
Previous close
$3.74
Today's open
$3.74
Day's range
$3.59 - $3.78
52 week range
$2.55 - $6.12
Profile about LTRN
show more
CEO
Panna Sharma
Employees
24
Headquarters
Dallas, TX
Exchange
NASDAQ Capital Market
Shares outstanding
11184423
Issue type
Common Stock
Popular stocks like LTRN
LTRN industries and sectors
Healthcare
Biotechnology & Life Sciences
News on LTRN
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
Business Wire • Dec 3, 2025
2 sub‑$10 AI stocks to outperform Palantir in 2026, according to ChatGPT‑5
Palantir Technologies (NASDAQ: PLTR) has grown into a dominant force in AI-driven data analytics, securing lucrative government contracts and expanding its mission-critical intelligence business.
Finbold • Nov 23, 2025
Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
Lantern Pharma Inc. ( LTRN ) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST Company Participants Panna Sharma - President, CEO & Director Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Reggie Ewesuedo Conference Call Participants Igor Astsaturov Presentation Panna Sharma President, CEO & Director Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar.
Seeking Alpha • Nov 21, 2025
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
Lantern Pharma Inc. ( LTRN ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Presentation Operator Good morning, and welcome to our third quarter 2025 earnings call. As a reminder, this call is being recorded [Operator Instructions].
Seeking Alpha • Nov 13, 2025
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Q3 Press Release - BTM.
Business Wire • Nov 13, 2025
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET.
Business Wire • Nov 6, 2025
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.
Business Wire • Oct 30, 2025
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
DALLAS--(BUSINESS WIRE)--LP-284 at 25th LL&M Congress & CMR.
Business Wire • Oct 28, 2025
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025.
Business Wire • Oct 24, 2025
Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184.
Business Wire • Sep 16, 2025
¹ Disclosures
Invest in Lantern Pharma Inc.
Open an M1 investment account to buy and sell Lantern Pharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.